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Transglutaminase 2 (TG2) is an allosteric enzyme ubiquitously expressed in human 
tissue. This versatile enzyme has both Ca2+ -dependent, transamidase and GTPase activities. 
TG2’s Ca2+ -dependent transamidase activity is linked to many different diseases; most notably 
neurodegenerative diseases like Parkinson’s. Initial Ca2+-dependent, TG2 mediated post-
translational modification of pathogenic proteins – including α-synuclein, tau, and β-amyloid—
increases their aggregations potential. As the disease progresses, neuronal damage causes a loss 
of Ca2+ homeostasis (i.e. increasing intracellular Ca2+ concentrations) and further activation of 
TG2; these increased activities further facilitate the formation of pathogenic protein oligomers. 
As such, the exacerbated symptoms of neurodegenerative disease can, in part, be attributed to 
this destructive cycle. The allosteric mechanism by which Ca2+ controls TG2’s transamidase 
activity is not fully understood. The currently accepted model posits that Ca2+ binding to TG2 
prior to the protein substrate (i.e. α-synuclein) induces conformational changes necessary for 
substrate binding and catalytic turnover. However, our preliminary data, using α-synuclein as a 
model substrate, challenges this theory; our model indicates that Ca2+ binding occurs after 
enzyme-substrate complex formation. That is, Ca2+ activates the TG2: α-synuclein complex. In 
light of this data, we aim to answer the question “What role does Ca2+ have in activating of the 
 
 
TG2: substrate complex?” We hypothesize that Ca2+ binding to the complex increases the 
stability of the enzyme: substrate complex, thereby increasing the rate of catalysis. Using Surface 
Plasmon Resonance (SPR), we have shown that the interactions between TG2 and α-synuclein 
do not adhere to a simple 1:1 binding model; as such, possible binding models for 
macromolecular complex formation are presented. We have also identified potential Ca2+- 
binding regions on TG2 using multiple alignments. We expect our findings will be beneficial in 
developing an accurate model for TG2 activation, which can further be used to develop 
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Section 1. BACKGROUND 
1.1 Neurodegenerative diseases are progressive and incurable. As the population ages in 
America, the occurrence of neurodegenerative disease is becoming significant. 
Neurodegenerative disease is defined as the progressive loss and/or death of neuronal cells. This 
progressive loss of neuronal cells leads to the loss of both motor and memory function [25]. 
Alzheimer’s and Parkinson’s disease are the most prevalent of the neurological disorders. 
Alzheimer’s disease affects roughly 16 million Americans and is currently the 6th leading cause 
of death in the United States; eclipsing both breast and prostate cancer deaths combined [11]. 
Similarly, Parkinson’s disease affects ~1 million Americans, with an average of 60,000 new 
cases diagnosed each year [6]. As a whole, neurodegenerative diseases cost the nation 277 billion 
dollars; and this figure is expected to increase in the upcoming years. Currently, there is no cure 
for these diseases as most medicines only reduce the severity of the symptoms [24].  
 
1.2 The Ca2+- dependent transamidase activity of transglutaminase 2 (TG2) leads to α-
synuclein oligomerization and aggregation in the diseased brain. A hallmark characteristic of 
both Alzheimer’s and Parkinson’s disease is the formation of both toxic protein oligomers and 
plaques in the diseased brain; the toxic protein oligomers and aggregates of α-synuclein and tau 
proteins are the underlying cause of neuronal death. α-Synuclein and tau are intrinsically 
disordered proteins which can form protofibrils, higher-order protein oligomers, and protein 
aggregates that induce disruption of cellular homeostasis [15-16].  There are numerous factors 
which trigger the formation of these protofibrils and oligomers, including the Ca2+-dependent, 
post-translational modification by transglutaminase 2 (TG2). TG2 post-translationally modifies 
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both α-synuclein and tau proteins; these modifications result in proteins that are more prone to 
oligomerize and aggregate. [15-16]. 
Oligomerization of the pathogenic proteins leads to the formation of protein polymers 
that causes damage to the neuronal cells [15-16,18,30-31]. The TG2-mediated modification of 
these proteins can lead to the further damage of neurons, eventually ending in cell death. This 
pathway is illustrated in Figure 1. Damaged cells are also known to contain low levels of GTP 
and high levels of Ca2+. This, along with oxidative damage, further promotes Ca2+-dependent 
TG2 transamidase activity [15-16,18,30-31]. For example, in Parkinson’s disease α-synuclein 
fibrils are key in the onset of the disease, as they are most abundant in intraneuronal Lewy bodies 
[15-16,39] (Figure 2). Studies have shown that TG2 catalyzes the formation of high molecular 
weight aggregates of α-synuclein which are characterized by protease resistant isopeptide bonds. 
It should be noted that α-synuclein can aggregate in the absence of TG2, with the potential for 
products to progress into fibrils [15-16,39]. Damaged neurons show increased Ca2+ levels and 
oxidative stress, both of which increase the Ca2+- dependent activity, ultimately leading to 
increased oligomerization, protein aggregation, and eventually, neuronal death (Figure 1) [15-
16,18,30-31]. However, the TG2-mediated post-translational modification and subsequent 
aggregation of modified α-synuclein represents a major oligomerization/aggregation pathway in 
both Parkinson’s and Alzheimer’s disease. 
 
 














Figure 1: TG2 activation in damaged neurons. TG2 Ca2+-dependent activity becomes uncontrolled 
due increased Ca2+ and oxidative stress induced by initial neuronal damage in the brain. 
 




1.3 TG2’s Ca2+- dependent activity proceeds through mechanism common to all members 
in the super family. TG2 performs post-translational modifications of proteins via an initial 
deamidation and subsequent transamidation at specific reactive Gln residue. In these reactions, a 
strictly conserved, nucleophilic cysteine residue (Cys277 in homo sapiens and mouse TG2) 
nucleophilically attacks the J- carbon of the peptide bound, glutamine side chain of a reactive 
Gln residue [16,17] (Figure 3). The result of these first steps of catalysis is the formation of a 
thioester acyl-enzyme intermediate concurrent with ammonia release. Water or a primary amine 
can subsequently perform a nucleophilic attack on the thioester bond. Attack by a water 
molecule results in deamidation of the Gln residue (i.e. Gln to Glu; Figure 4A). Attack with a 
Figure 2: α-Synuclein oligomerization pathway leads to formation of Lewy bodies. Aggregation of 
α-synuclein is first observed in the form of granular deposits. From here, the deposits have the chance 
of progressing into Lewy bodies, which are pathognomonic to Parkinson’s disease [2].   
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primary amine results in posttranslational modifications (Figure 4B). Although there has been 
speculation about what reaction is preferred, it is not fully understood which activity is favored. 
The site of transamidation activity consists of a catalytic triad: Cys277, His335, and Asp358 [16-
17,27]. The Cys277 has been shown to be pivotal for transamidation activity. Two tryptophan 
residues (Trp241 and Trp332) form a catalytic tunnel which further stabilize the thioester 
intermediate during catalysis [16-17,27]. The two residues can be viewed as a “drawbridge” for 







Figure 3: The catalytic triad is the center for TG2 Ca2+-dependent activity. The catalytic triad 
(pictured in yellow) consists of Cys277, His335, and Asp358. Substrates must form a thioester linkage 
with Cys in order to initiate binding. Trp332 and Trp 241 act as a drawbridge for binding substrates. 
 






1.4 Even though the Ca2+- dependent transamidase activity of TG2 in different pathways 
has been well documented, the allosteric mechanisms governing TG2’s activity remain 
undefined. Understanding how TG2 is regulated is important in order to comprehend both the 
biological and pathological activities of TG2. TG2 possesses numerous catalytic activities; most 
importantly the Ca2+ -dependent transamidase and Ca2+-independent, GTPase activities 
[10,12,16-17,27, 28-29,32]. Studies have shown that TG2 is the D-subunit of a G Protein in 
different signaling pathways [12,16-17,20,27]. TG2 is further known to exhibit Ser/Thr kinase 
and protein disulfide isomerase (PDI) activities [16-17,29]. The Ca2+-dependent and GTPase 
activities are mutually exclusive and reciprocally regulated such that Ca2+ inhibits GTPase 
activity and vice versa. 
Figure 4: Multiple pathways of transamidation. After forming the acyl-enzyme intermediate, TG2 
can (A) react with water to produce a glutamate residue, (B) react with a primary amine, or (C) react 
with the H-group of a lysine resulting in a crosslinked protein. 
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 In the current model of TG2 regulation, the global conformation of TG2 is proposed to be 
directly related to these competing activities [20,27]. TG2 consists of four major domains: a N-
terminal E-Sandwich, catalytic core, and two C-terminal E-barrels (Figure 5). TG2 with 
nucleotides bound such as GTP and ATP adopt a “closed” conformation supported by x-ray 
crystallography structures [20]. In this conformation, the C-terminal E-barrels fold over the 
catalytic core, potentially inhibiting any potential substrates from binding and concurrently 
forming a nucleotide binding site [20]. In contrast, TG2 is proposed to adopt an extended, or 
“open” conformation, allowing full access to the active site tunnel, thus supporting 
transamidation activity. In this conformation, the C-terminal E-barrels are stretched out, exposing 
the catalytic core [27].
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1.5 The current accepted mechanism of TG2 activation of Ca2+ - dependent activity does 
not fully account for its in vivo activity. The currently accepted allosteric mechanism 
governing the activation of TG2 suggests that Ca2+ binding to six sites on the enzyme promotes 
and stabilizes the “open” conformation and allows the substrate to bind [7]. Conversely, in the 
absence of Ca2+, the enzyme is proposed to adopt a more closed structure, thus preventing 
transamidation activity. There are numerous studies, however, which suggests that this 
mechanism may not account for in vivo TG2 activity. Also, the crystal structure of the “open” or 
Ca2+-dependent active conformation, does not contain any Ca2+, even though the structure was 









Figure 5: TG2 undergoes a large conformational change upon GTP binding. With Ca2+ 
independent activity, TG2 is seen folded in on itself, forming a “closed” conformation (PDB: 4PYG) 
[20]. Ca2+ dependent activity requires the enzyme to be in an “open” conformation (PDB: 2Q3Z) [27]. 
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for Ca2+ determined with the non-natural substrate Cbz-Gln-Gly (ZGG). This structure did 
contain a covalently bound, peptide mimetic inhibitor, however, which might be responsible for 
the unique “open” structure. 
Another potential issue is that most studies that have been done on TG2 use non-
physiological substrates such as Cbz-Gln-Gly and uncommon substrates such as casein. These 
models could provide an inaccurate representation of how TG2 is being activated. For example, 
the Km for Ca2+ determined with the artificial substrate Z-Gln-Gly was higher than the [Ca2+] 
concentration in the cell. The apparent Km for GTP is lower than what the [GTP] concentrations 
are in the cell. These data suggest, then, that TG2 is not active as a transamidase in the cell under 
normal physiological conditions; however, data show that TG2 is active as a transamidase in the 
cell when Ca2+ levels in nM range and GTP at PM ranges [36]. 
 
1.6 In order to resolve the mechanism and advance our understanding of TG2’s biological 
and pathological activities, the research here is focused on defining the role of Ca2+ in the 
formation of the TG2: α-synuclein complex. In order to define the allosteric mechanism 
governing TG2 Ca2+- dependent activity, we have undertaken substrate and Ca2+ binding and 
kinetic studies using α-synuclein as a model substrate. α-synuclein structure consist of three 
reactive Gln residues (Q79, Q99 and Q109) and two reactive Lys residues (K32, K80) [35]. We 
believe that using a physiological substrate will provide a more accurate activation mechanism. 
These sites are the targets of transamidation activity from TG2. The mechanism behind TG2’s 
activation has been controversial because the current model suggests that TG2 can be activated 
by Ca2+ alone [7]. Preliminary data from our lab suggested that Ca2+ may be activating TG2 after 
substrate binding; as such we hypothesize that Ca2+ is activating the TG2: α-synuclein complex, 
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rather than the enzyme itself, possibly by inducing catalytically relevant conformations in the 
ternary complex (Figure 6). In order to test this hypothesis and determine a functional role for 
Ca2+, the work presented here aims to: 
1.  Determine if α-synuclein binds to TG2 in the absence of Ca2+ and the effects of 
Ca2+ and electrostatics on the formation of the TG2: α-synuclein complex  
2.  Identify the role of Ca2+ in promoting or facilitating complex formation 










Figure 6: The currently accepted model of activation of TG2 versus our predicted model. 
Preliminary data confronts the idea that TG2 is activated by Ca2+ alone. We believe that there is a 
cooperative mechanism between the substrate and Ca2+ that activates TG2. 
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1.7 If Ca2+ is not required for substrate binding, then it must play a role somewhere else in 
the mechanism. For example, tightening the complex, conformational changes to promote 
catalysis or facilitating product release are all potential roles that Ca2+ provides. We used SPR, 
LRET/Tb3+ binding studies, and FURA-2 analysis to confirm our hypothesis. Bioinformatics was 
used to identify other possible Ca2+ binding sites. We determined how Ca2+ affects the activation 
of the TG2: substrate complex. Understanding how TG2 is activated will give us a better idea of 
why it affects patients suffering from neurodegenerative diseases. Furthermore, it will strengthen 
our foundational knowledge of the mechanism, which could lead to synthesis of effective TG2 
inhibitors.
 
Section 2. DETERMINING the ROLE of Ca2+ IN ACTIVATING THE TG2 α-
SYNUCLEIN COMPLEX 
Introduction 
The onset of neurodegenerative disease can be linked, in part, to catalytic activity 
between TG2 and α-synuclein [31,33]. Prior to modification, TG2 must first bind to α-synuclein 
and form the enzyme-substrate complex. Ca2+ plays a significant role in this mechanism as it is 
required for catalytic activity [31,33]. The currently accepted model of activation of TG2 shows 
that Ca2+ facilitates binding of α-synuclein by causing a conformational change in the enzyme’s 
structure; however, our lab has evidence that this model may not be entirely accurate. In order to 
investigate the macromolecule assembly between the two proteins, we used Surface Plasmon 
Resonance (SPR). SPR uses evanescent waves to excite a gold film. The excitation creates 
plasmons that are sensitive to changes in molecular weight (Figure 7) [22,38]. We can use this to 
effectively study protein-protein interactions, and in this case TG2 complex formation [7]. In our 
studies we use a C277A mutant of TG2 that allows for complex formation but prevents catalytic 
turnover. This mutant has the same inherent binding affinities for both substrate and Ca2+ as the 
WT enzyme. 
 











Figure 7: Illustration of Surface Plasmon Resonance. Depiction of how Surface 
Plasmon Resonance works [Nicoya]. Any conformations changes to the ligand will 
cause a shift in the resonance. 
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TG2 has many substrates however in this study we wanted to focus on three specific 
substrates. We start with TG2’s interaction with α-synuclein which in this study, is being used as 
our model substrate. α-Synuclein structure is intrinsically disordered, which can potentially show 
a unique binding mechanism [23]. We also look at TG2’s interaction with casein and Cbz-Gln-
Gly. Casein’s structure is known to contain order in its structure while Cbz-Gln-Gly is a non-
physiological substrate primarily used for measuring transamidation assays. These structures are 
important because they are more popularly used in the field when studying TG2’s catalytic 
activity. The majority of TG2’s activation mechanisms that have been proposed have been based 
off of the use of these substrates [5,36].  
SPR is further being used to determine if Ca2+ has a role in stabilizing the enzyme-
substrate complex. In this study we started by focusing on complex formation in the absence of 
Ca2+, as preliminary studies suggest that this is possible. We wanted to confirm this by 
investigating the interaction of TG2 and α-synuclein in a Ca2+-free environment. Next, we 
investigated Ca2+ role regarding the stability of the complex i.e. if Ca2+ binding adds integrity to 
the TG2: α-synuclein complex. Ca2+ could also have an effect on the rate of complex formation. 
When α-synuclein first interacts with TG2, there could be a conformational change that allows 
Ca2+ to binding to available regions, which in term increase the speed at which the complex is 
formed. We propose that increasing Ca2+ does not have an effect on the association rate of α-
synuclein, but however the increase of Ca2+ results in a tighter complex, decreasing dissociation 
rates. 
Another point of interest is to study the effect of ionic strength on TG2. Ionic strength is 
important, as it can affect interactions between TG2 and α-synuclein [9,40]. For example, if 
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complex formation is driven by electrostatics, altering ionic strength can affect the affinity 
towards α-synuclein. Studying this affect could lead to a more complete understanding of TG2’s 
activation mechanism. 
Finally, we use FURA-2 to investigate equilibrium binding between TG2 and Ca2+ in the 
presence and absence of α-synuclein. FURA-2 is a high affinity fluorescent probe that can 
measure low Ca2+ levels in solution. By using an EGTA buffer system, we can control available 
Ca2+ and measure binding as the complex continues to form [28]. We seek to find the 
relationship between TG2 and Ca2+ as well as make assumptions about the enzyme: substrate 
complex.
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Methods and Materials 
 
Materials 
The BCA assay kit, Ni+- NTA resin, and Tris-HCl buffer was purchased from 
Thermosphere Scientific (Waltham, MA). Glycerol was purchased from Research Products 
International (RPI; Mt. Prospect, IL). FURA-2 potassium salt was purchased from Enzo 
Lifesciences (Farmingdale, NY). All other chemicals were purchased from VWR International 
(Radnor, PA) and of the highest purity available. 
 
Overexpression of TG2 and α-synuclein 
Electrocompetent BL21STAR(dE3) E. Coli were transformed with either the plasmid 
containing wild-type TG2 (pET-17b backbone) or α-synuclein (p-Receiver 01 backbone, 
Gencopia) and allowed to recover for 1 hour in 1 mL of SOC Media. ~25 µL of media was 
transferred to a Luria broth plate containing 35 mg/mL kanamycin (TG2) or 10 mg/mL 
ampicillin (α-synuclein) for plasmid maintenance and incubated for ~12 hours at 37 ºC. 
Individuals colonies were chosen at random and allowed to grow in 5 mL of Luria broth at 37 ºC 
containing the respective antibiotic. The 5 mL culture was used to inoculate 1 L of LB medium 
overnight with antibiotic (~12 hours of incubation time), which was later used to inoculate a 20 
L carboy containing LB medium. The large-scale growths were carried out in a fermenter 
equipped with an air-inlet hose as well as a gas diffusion stone to provide bacteria with proper 
aeration. 0.75 g of kanamycin or 2.0 g of the ampicillin was added to the carboy as well as 1 mL 
of Antifoam 204 (Sigma Aldrich). ~10 mL of the overnight cells was added to the carboy and 
allowed to grow at a temperature of 37 ºC. This gave a starting optical density of roughly 0.010 
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A. Once an OD600 of ~0.6 – 0.7 A was reached, cells were immediately cooled to 20 ºC and 5.0 g 
of IPTG (final concentration 1 mM) was added to induce protein expression. Cells were allowed 
to further incubate for 18 hours. 10 mL of media was transferred to a separate container after 
incubation to test the cells for protein expression. Cells were harvested using a Sorvall LYNX 
4000 Centrifuge (5000 rpm for 10 minutes) and flash-frozen in liquid nitrogen, yielding between 
50 to 150 g of cell paste. The frozen cell pellets were stored at -80 ºC.  
 
Purification of Wild-Type and Mutant Forms of TG2 
Protein was purified using a combination of Ni2+- affinity chromatography and Q-
Sepharose ion exchange chromatography.  ~20 g of cell paste was thawed in ~250 mL of lysis 
buffer (50 mM Na-Phosphate, pH 8.0, 300 mM NaCl) and ~200 µg/mL of lysozyme with stirring 
for ~15 minutes. Cells were then lysed by sonication using a Branson Digital Sonicator for 6 
minutes (80% amplitude; pulse on: 59.9 seconds; pulse off: 30 seconds; max temp: 10 ºC). The 
lysate was clarified via centrifugation (10,000 rpm for 20 minutes using a Sorvall LYNX 4000 
Centrifuge). The remaining supernatant was allowed to batch bind with ~10 mL of Ni+-NTA 
Resin while rotating (2 hours; 4 ºC). Before being used for binding, the resin was pre-
equilibrated with 5 column volumes of Milli-Q and 5 column volumes lysis buffer. After batch 
binding the resin was spun down at 4500 rpm for 15 minutes. The remaining supernatant was 
discarded and the resin was loaded onto a glass column and washed with 10 column volumes of 
wash buffer (50 mM Na-Phosphate pH 8.0, 300 mM NaCl, 10 mM imidazole;1.5 mL/min). TG2 
was eluted with an elution buffer (50 mM Na-Phosphate pH 8.0, 300 mM NaCl, 750 mM 
imidazole) over a 300 mL linear gradient (1.5 mL/min). Fractions of interest were ran on a SDS-
PAGE gel (5% stacking/9% resolving, 150 Volts, 1 hour) and those containing TG2 were 
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dialyzed overnight (2 X 1L; 20 mM Tris pH 7.2, 50 mM NaCl, 1 mM DTT, 1 mM EDTA) at 4 
ºC. 
Dialyzed proteins were loaded onto ~10 mL of Q-SepharoseTM Fast Flow resin at 1.5 
mL/min. The resin was pre-equilibrated with 10 column volumes of Buffer A (20 mM Tris pH 
7.2, 1 50 mM NaCl, 1 mM DTT, 1 mM EDTA). The loaded protein was washed with 10 column 
volumes of Buffer A and eluted with 150 mL linear gradient of Buffer B (20 mM Tris pH 7.2, 
1M NaCl, 1mM DTT, 1 mM EDTA). Fractions of interest were analyzed SDS-PAGE (5% 
stacking/9% resolving; 150 Volts; 1 hour) and dialyzed overnight (2 X 1 L 20 mM MOPS pH 
7.2, 150 mM NaCl, 1 mM DTT, 1 mM EDTA) at 4 ºC. 
Purified protein was concentrated via centrifugation (4500 rpm; 15 minutes). A Vivaspin 
20 centrifugal concentration tube (50 kDa MWCO; Sigma Aldrich) was used to concentrate to 
~6 mg/mL. 10% glycerol was added dropwise, on ice, to the protein prior to flash-freezing and 
storage at -80 ºC. A BCA assay (Thermofisher) was performed to calculate the final protein 
concentration. 
 
Purification of α-synuclein 
Purification of α-synuclein follows the same initial Ni2+- affinity chromatography 
protocol with a few changes. α-synuclein lysis buffer consisted of 20 mM Na- Phosphate (pH 
8.0), 300 mM NaCl, and 1 mM PMSF. The wash buffer consisted of 20 mM Na- Phosphate (pH 
8.0), 300 mM NaCl, and 10 mM imidazole. Elution buffer consisted of 20 mM Na- Phosphate 
(pH 8.0), 300 mM NaCl, and 750 mM imidazole. Two SDS-PAGE gels (5% stacking/12% 
resolving; 150 V; 1 hour) were ran to test for fractions of interest. Fractions containing protein 
were transferred to Spectra/Por Dialysis tubing (3-5 MWCO; Spectra) and dialyzed initially for 
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one hour, then overnight (2 X 1 L 20 mM Tris- HCl pH 7.2, 150 mM NaCl, 1 mM DTT, 1 mM 
EDTA) at 4 ºC. After dialysis the protein was concentrated using a Vivaspin 20 centrifugal 
concentration tube (3 kDa MWCO; Sigma Aldrich). α-synuclein was concentrated to about 0.8 
mg/mL.  Protein was aliquoted into small centrifuge tubes without addition of 10% glycerol. 
Protein was flash-frozen and stored at -80 ºC. A BCA assay was ran to confirm protein 
concentration. 
 
Surface Plasmon Resonance (SPR) Experiments 
SPR data was all recorded on an OpenSPR system (Nicoya Lifesciences). For all experiments 20 
mM MOPS (pH 7.2), 150 mM NaCl, 1 mM DTT, and 0.005% Tween 20 was used for as a base 
running buffer. Depending on experimental conditions 1 mM EGTA and 10 nM-10 mM Ca2+ 
were also added to the running buffer. Purified TG2 or α-synuclein (200 µL; 50 µg/mL) was 
immobilized on a gold plated, -COOH functionalized chip according to manufactures 
instructions. TG2 was previously dialyzed overnight in a running buffer containing 10 mM 
EGTA. Amine Coupling Kit (Nicoya) was used to immobilize protein at a flow rate of 20 
µL/min. After injection of protein, a blocking solution (200 µL) followed by regeneration 
solution (200 µL of 1 M NaCl) was allowed to run through the system (10 min). With α-
synuclein on the chip, regeneration solutions consisted of 1M NaCl and 10 mM NaOH.  
All experiments started with injections of small amounts of analyte to dictate 
concentration range (1nM – 15µM ). Depending on dissociation efficiency, the chip was 
reconditioned with the regeneration solution at a pump speed of 50 µL/min for ~1 min then 
allowed to run for an additional 3 min before reverting back to 20 µL/min. Data obtained over a 
variety of chips to eliminate chip-to-chip variability. 
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Ca2+ Binding Studies using FURA-2 Fluorescent Probe 
Ca2+ binding studies with FURA-2 were conducted using a Biotek Cytation5 Reader. 
Buffer A (100 mM MOPS pH 7.2, 750 mM NaCl, 50 mM EGTA) and Buffer B (100 mM MOPS 
pH 7.2, 750 mM NaCl, 50 mM EGTA, 50 mM CaCl2) were used to control Ca2+ concentrations. 
A standard curve was also prepared for data analysis (ThermoFisher). Samples and standards 
were prepared in black Eppendorf tubes to protect from light.  Prepared samples were allowed to 
incubate for 1 hour at room temperature. After incubation, 3 µM of FURA-2 probe was added to 
each tube and samples were aliquoted in triplicate to a black 96-well reading plate. The 
fluorescence of each sample was read immediately at 25 ºC. Samples were subjected to a 
constant excitation at 510 nm and the emission was measured from 300 nm to 600 nm. 
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Data Analysis 
Surface Plasmon Resonance (SPR) Analysis 
The amount of TG2 or ligand α-synuclein immobilized to each chip was calculated from 
the differences in the wavelength before and after addition. The ligand immobilization level, 
which varied with each chip and was used to determine the theoretical maximal signal response, 
Rmax, using eqn (1) 
 
where analyte MW and ligand MW are the molecular weights of the analyte and ligand, 
respectively. The ligand immobilization level was calculated from the change in wavelength 
before and after addition of ligand. SPR curves were generated by plotting arbitrary response 
units (RU) vs. time. Responses are derived directly from changes in wavelength. The SPR 
sensorgrams were reference corrected and blank injections were subtracted from the observed 
data. Sumerograms for individual experiments were fitted to either a 1:1 (Langmuir model, eqn 
2) or 1:2 state binding model (eqn 3) [Biacore Lifesciences]. For a 1:1 interaction, data were 
globally fitted to the following differential eqn using Tracedrawer (v 1.8) using numerical 
integration:  
 
where Y is the observed RU, c is the concentration of the ligand, ka is the association constant (M 
s-1) and kd is the dissociation constant (s-1). Bmax is the maximum signal from the ligand at 
saturation. The observed RU at time = 0 must be zero. 
eqn 1  
eqn 2  
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For the 1:2 state binding model, data were globally fitted to the following differential eqn using 
Tracedrawer (v 1.8) using numerical integration: 
 
where Y is the observed RU, AB and AC are the individual observed RU of the two 
conformations of ligand immobilized on the chip, c is the concentration of the ligand, ka1 is the 
association constant of conformation state one(M s-1), kd1 is the dissociation constant of 
conformation state two(s-1), ka2 is the association constant of conformation state two(M s-1), and 
kd2 is the dissociation constant of conformation state two(s-1). Bmax is the maximum signal from 
the ligand in conformation state one at saturation. Cmax is the maximum signal from the ligand in 
conformation state two at saturation. The observed RU of the two conformations at time = 0 
must be zero. 
Goodness of fit was determined by a Chi-Square Test with the equation: 
 
where o is the observed value and e is the expected value. 
 
eqn 3  
eqn 4  
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TG2 - Ca2+ binding analysis with FURA-2 
The Kd of Fura-2 for Ca2+ under our experimental conditions was determined 
fluorometrically using a ratiometric method (λ1 = 340 nm, λ2 = 380 nm). The Kd was determined 
using the equation:  
where Rmin and Rmax are the ratios of the fluorescence intensities at 340 and 380 nm determined 
at 0 µM and 39.5 µM Ca2+, respectively. R is the ratio of florescence intensities measured at a 
specific Ca2+ concentration.  Kd is the dissociation constant of Ca2+ binding for Fura-2. Finally, 
Q is a fluorescence correction factor, F380max/F380min, where F380max and F380min are the 
fluorescence intensities at 380 nm determined at 0 and 39.5 µM Ca2+, respectively. The apparent 
Kd for Fura-2 was determined by extrapolation of the slope from log-log plots of fluorescent 
intensities at known standard concentrations of Ca2+ vs. log[Ca2+]. Standard Ca2+ concentrations 
were prepared with an EGTA buffer system that follows the equation: 
 
Where KdEGTA is the dissociation constant of Ca2+ binding for EGTA [21]. CaEGTA was made 
by mixing 50 mM CaCl2 and 50 mM EGTA. Standards were prepared in triplicate. Reported 
errors are ± standard deviation from triplicate experiments.  
 
eqn 5  
eqn 6  
 
  24 
Ca2+ binding curves were generated by plotting the ratio of bound to total Ca2+ 
concentration ([Ca2+]Total-[Ca2+]Free/[Ca2+]Total) vs. [TG2] in µM. Equilibrium binding curves were 
fitted to either a one-site specific binding equation or an allosteric binding equation: 
where Bmax is the maximum binding fraction, [A] is the concentration of TG2, Kd is the binding 
constant, and h is the hill slope. One-site specific binding assumes the hill slope is equal to one. 
The Bmax were not constrained to be below one.  
 
Analysis of Dissociation Rates 
 Dissociation curves were fitted to the following decay equation: 
 
where Y is the signal response, Y0 is the response at time = 0, plateau is the response at infinite 




eqn 7  
eqn 8  
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Results 
Macromolecule Assembly in the Presence and Absence of Ca2+ 
To investigate the interaction between TG2 and α-synuclein in various Ca2+ 
environments, we used Surface Plasmon Resonance (SPR). We first observed complex formation 
and dissociation in the absence of Ca2+ (10 mM EGTA) with varying α-synuclein. A sensorgram 
depicting the association and dissociation of the complex with TG2 on the chip surface was 
generated. We also tested the same interaction with varying TG2. Both TG2 and α-synuclein 
were dialyzed in an EGTA buffer to remove any endogenous Ca2+.  Sensorgrams with both 
interactions at 0 µM Ca2+ are shown in Figure 8A-B. Table 1 and 2 lists the resulting binding 
constants. A 1:2 state binding model was used when TG2 was on the chip and Langmuir’s 1:1 
state binding model for when α-synuclein was on the chip. The 1:2 state binding model assumes 
two conformational states of TG2 in solution form two separate complexes. Sensorgrams 
depicting complex formation with varying Ca2+ concentrations were also generated (Figure 9 and 
Figure 10). Some curves were removed from the fit due to calculated oversaturation on the chip 
(eqn 1). As a result, some plots only consist of three concentrations while others contain four. 





  26 
 
  





















Figure 8A-B: Binding of TG2 and α-synuclein in the presence of 10 mM EGTA. (A) 
SPR sensorgram of complex with varying α-synuclein. Experiment conditions included 
a running buffer with 20 mM MOPS pH 7.2, 150 mM NaCl, 1 mM DTT, 10 mM EGTA. 
Data was globally fitted to a 1:2 state binding model (eqn 3). (B) SPR sensorgram of 
complex with varying TG2 under same experimental conditions. Data was fitted using 
Langmuir’s 1:1 binding model (eqn 2). 
A  
B  
































Table 1: Binding constants from TG2: α-synuclein complex formation at 0 µM Ca2+ with varying α-synuclein 
ka1 (M s-1) kd1 (s-1) KD1  (M) ka2 (M s-1) kd2 (s-1) KD2  (M) Chi-Square 
5390 r 224 2.20 *10-3 r  3.90 
*10-6 
4.08 *10-7r  1.77 
*10-8 
1240r 347 2.50 *10-3 r 6.38 
*10-7 






Table 2: Binding constants from TG2: α-synuclein complex formation at 0 µM Ca2+ with varying TG2 
ka (M s-1) kd (s-1) KD (M) Chi-Square 
18900 r 125 3.46*10-3r 2.16*10-6 1.84*10-7 r 1.33*10-9 54.58 
 


















































































































Figure 9A-F: TG2: α-synuclein complex formation in low Ca2+ environments. SPR sensorgrams of 
complex formation with varying α-synuclein ranging from 10 nM to 10 µM free Ca2+. Experiment 
conditions consisted of a running buffer with 20 mM MOPS pH 7.2, 150 mM NaCl, 1 mM DTT, 10 
mM EGTA. Data was fitted using a 1:2 state binding model (eqn 3).  
A  B  C 
D E F 
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Figure 10A-E: TG2: α-synuclein complex formation in high Ca2+ environments. SPR sensorgrams 
of complex formation with varying α-synuclein ranging from 100 µM to 1 mM free Ca2+. Experiment 
conditions consisted of a running buffer with 20 mM MOPS pH 7.2, 150 mM NaCl, 1 mM DTT, 10 
mM EGTA. Data was fitted using a 1:2 state binding model (eqn 3).  
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Figure 11A-F: Resulting binding constants from complex formation in various Ca2+ 
environments. Resulting binding constants derived from a 1:2 state binding model (eqn 3). The figures 
display the association, dissociation, and equilibrium constants of the two conformations of TG2. 
A  B  C  
D  E  F  
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Table 3: Binding constants from TG2: α-synuclein complex formation at various Ca2+ concentrations 
 ka1 (M s-1) kd1 (s-1) kD1 (M) ka2 (M s-1) kd2 (s-1) kD2 (M) Chi-Square 
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TG2 Complex Formation with Casein and Cbz-Gln-Gly 
To investigate the non-physiological and uncommon interactions with TG2, we used SPR 
to study complex formation with Cbz-Gln-Gly and casein in various Ca2+ environments. Cbz-
Gln-Gly showed unfavorable binding with TG2 in both Ca2+ free and Ca2+ rich environments 
(Figure 12A-C). Data were not fitted to due to a poor response signal. TG2 interactions with 
casein however showed complex formation in both Ca2+-free and Ca2+ rich environments (Figure 
13A and 13B). Resulting binding constants from the 1:2 state fitting model are displayed in 
Table 4. 
 
Effect of Ionic Strength on TG2: α-synuclein complex formation 
Current studies have used a constant physiological based ionic strength to investigate 
complex formation (0.3 M ionic strength). To determine the effect on the association of the TG2: 
α-synuclein complex, we used SPR to establish this relationship. Sensorgrams showing complex 
formation at various ionic strengths were generated (Figure 14). Resulting binding constants are 
displayed in Table 5. 
 
TG2 Binding Interactions with Ca2+ using FURA-2 as a Fluorescent Probe 
TG2 interactions with Ca2+ were further investigated using FURA-2 to measure Ca2+ 
uptake at low concentrations. Ca2+ interactions between C277A, and the C277A: α-synuclein 
complexes were also studied (Figure 15A-F). Results were fitted to either the one-site specific 
hyperbolic equation or the allosteric binding equation (eqn 7; Table 6).
 











































































Figure 12A-C: TG2 interactions with Cbz-Gln-Gly at various Ca2+ concentrations. 
SPR Sensorgraphs of TG2 interacting with ZGG at 0 µM, 1 mM and 10 mM free Ca2+, 
respectively. Typical experimental conditions consisted of a running buffer with 20 mM 


















































Figure 13A-B: TG2 interactions with casein at various Ca2+ concentrations. SPR 
sensorgrams of TG2 complex formation with casein at 0 µM and 1 mM free Ca2+, 
respectively. Typical experimental conditions consisted of a running buffer with 20 mM 
MOPS pH 7.2, 150 mM NaCl, and 1 mM DTT. Data was fit to Langmuir’s 1:2 binding 
















Table 4: Binding constants derived from TG2: casein complex formation at 0 PM Free Ca2+. 
 ka1 (M s-1) kd1 (s-1) kD1 (M) ka2 (M s-1) kd2 (s-1) kD2 (M) Chi-Square 



























































































Figure 14A-B: Effects of complex formation with varying ionic strengths. SPR sensorgrams of TG2 
complex formation with casein at 0 µM and 1 mM free Ca2+, respectively. Typical experimental 
conditions consisted of a running buffer with 20 mM MOPS pH 7.2, 1 mM DTT, and 10 mM EGTA. 
Data was fitted to a 1:2 binding model (eqn 3). 
 












Table 5: Binding constants derived from TG2: α-synuclein complex formation with varying ionic strength  
 ka1 (M s-1) kd1 (s-1) kD1 (M) ka2 (M s-1) kd2 (s-1) kD2 (M) Chi-Square 
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Figure 15A-E: The effects of Ca2+ binding on TG2 and mutants. Ca2+ binding to TG2 
in 1 µM (A) and 5 µM (B) free Ca2+, respectively. α-synuclein concentration was kept 
constant at 5 µM. Typical experimental conditions consisted of a 5x EGTA buffer 
system with 150 mM MOPS pH 7.2, 500 mM NaCl, and 50 mM EGTA. 2 µM of BSA 
was also added to each sample. Data was fitted to the allosteric equations (eqn 8), with 
the preferred model being shown. Data was recorded in triplicate. Error bars represent 
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Table 6: Binding constants derived from TG2: Ca2+ binding using FURA-2 as fluorescent probe 
 Bmax kd (PM) h Goodness of Fit (R-
Square) 
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Discussion 
We first investigated TG2 α-synuclein and complex formation in a Ca2+ free environment 
using Surface Plasmon Resonance (SPR). We wanted to confirm our proposed model of complex 
formation being capable without Ca2+. We believe that previous studies generated a different 
model due to the use of both non-physiological and uncommon substrates.  
We found that complex formation is obtainable in the absence of Ca2+. This result 
directly challenges the currently accepted model of Ca2+ inducing conformational changes to 
TG2 alone. Because Ca2+ is required for catalytic activity, it is believed that Ca2+ must play a 
role elsewhere in the mechanism. The resulting Chi-Square of the two fits were found to be 
32.77 with TG2 on the chip and 40.32 with α-synuclein. We think that these high deviations of 
the fits are due to a more complicated binding mechanism that our models do not account for. 
The 1:2 state binding model states there are two conformational states of TG2, each capable of 
binding α-synuclein with different ka and kd. Although we understand that TG2 exist as two 
forms in solution, we believe that the mechanism of complex formation is more complicated than 
this model allows [32,36]. We propose three possible models of TG2 complex formation that we 
believe to be a more accurate representation (Figure 17A-C). As a result of preliminary studies, 
each model assumes that the dissociation of the complex is a single exponential (Figure 16). 
Model B is favored, as one dissociation from one conformational state is most likely. α-
Synuclein’s intrinsically disordered structure could also make additional conformational changes 
to the complex more likely. The conformational changes could be thermodynamically driven, in 
which complex dissociation would only be obtainable at a once a specific conformation state is 
obtained.
 












































































Figure 16: Effects of α-synuclein concentration on dissociation rates of TG2: α-synuclein complex. 
Plotted Kobs from dissociation against α-synuclein concentration. Kobs were determined from eqn (9). 
 






Figure 17A-C: Potential mechanistic models for TG2: α-synuclein complex 
formation. We believe that TG2 complex formation is more intricate than what the 1:2 
state binding model offers. In these models, ka represents the association constant, kd 
represents the dissociation constant, kconf represents the constant regarding 
conformational change to the enzyme: substrate complex, and K* represents the 
equilibrium constant of the two states of the enzyme.  (A) The two conformation states 
TG2 exist in are allowed to form and dissociate the complex. This model assumes kd1 = 
kd2. (B) The two states of TG2 can form complexes however a secondary conformational 
change occurs in order for dissociation to proceed. (C) Both states of TG2 can form the 
complex however only one conformation can dissociate. All three models assume the 
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Since we believe Model B is representative of what is actually occurring, it is important 
to note that the second conformational change could potentially be a rate determining step. For 
the sake of simplicity, the model does not show interchanging between the two complexes. It is 
believed that α-synuclein is constantly in motion while being bound to TG2, and this extra 
flexibility could induce the constant restructuring of the complex. Each model also assumes that 
only one α-synuclein is binding to TG2. In physiological conditions, it is quite possible that 
actually two α-synuclein bind to TG2 [13]. This adds an extra layer of possible conformational 
changes and unique complexes that TG2 can have. In the future, SPR could be used to determine 
how many substrates are binding, as we could calculate our expected change in response based 
off of molecular weight. 
When viewing the effects of Ca2+ on the formation of the complex it appears the varying 
Ca2+ concentrations are affecting the association rate constants. The association constants of the 
first conformational state of TG2 appears to favor higher concentrations of Ca2+. The second 
state inversely appears to have an increase of the association rate constants in low concentrations 
of Ca2+. Because our fitting model is not an accurate representation of the mechanism, we cannot 
make definite claims about the data. We are limited to observing trends in the rate constants. It 
would be insightful to compare the trends if the data gets fit to an appropriate model. 
We also have to take a qualitative approach when analyzing the effect of ionic strength 
on the interactions between TG2 and α-synuclein.  Looking at the characteristics of the curves, it 
does appear that decreasing ionic strength does allow complex formation to come to an 
equilibrium much quicker than at physiological conditions. As with the Ca2+ association data, it 
would be interesting to compare binding constants with a more accurate binding model. 
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 Furthermore, we investigated TG2 interactions between Cbz-Gln-Gly and casein in both 
Ca2+ free and Ca2+ rich environments. Binding with Cbz-Gln-Gly showed little to no binding to 
TG2 in the absence of Ca2+. As the Ca2+ levels increased, it appeared that binding became more 
favorable. This interaction is noteworthy as it appears to not follow the same binding mechanism 
as α-synuclein. The inability to form the complex in a Ca2+ free environment is uncharacteristic 
of a physiologically relevant substrate of TG2. It is also important to note that Cbz-Gln-Gly is 
much smaller than any physiological substrate (0.3 kDa) and its structure is simplistic, which 
could also be why its binding mechanism is unique. The small structure would likely not cause a 
conformational change to the complex upon binding. Due to the popular use of Cbz-Gln-Gly in 
determining transamidation activity, it is understood why the currently accepted model for TG2 
activation states that it needs Ca2+ before the substrate can bind.  
TG2’s interactions with casein showed it can bind in both the absence and presence of 
Ca2+. Casein was able to bind to TG2 in a Ca2+ free environment at a rate comparable to α-
synuclein. Dissociation of the complex conversely appeared to be occurring at a faster rate. The 
versatility of TG2 allows for binding of a plethora of different proteins and molecules; however, 
it is expected that the stability of the different complexes formed will not be uniform. To add to 
this, the intrinsically disordered nature of α-synuclein allows for extra flexibility in finding a 
stable conformation of the TG2: α-synuclein complex [23]. Casein’s structure does not follow 
this characteristic however, it is suspected that casein contains regions of disorder in areas that 
TG2 binding is likely.  
FURA-2 studies investigate TG2- α-synuclein complex formation at different 
concentrations of Ca2+ and α-synuclein. We wanted to establish how TG2 interacts with α-
synuclein and Ca2+, specifically at low Ca2+ concentrations. We did not observe any significant 
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changes in Ca2+ binding between WT TG2 and C277A. Also, the binding constants obtained are 
not reflective of what we observe in the data. We believe that there is a large amount of error 
present in the fitting model. Because of this, we decided to take a qualitative approach in 
analyzing this data. What we can determine is that there is clear binding of Ca2+ to the 
apoenzyme. Although we do observe Ca2+ binding with TG2 alone, we don’t believe it is overly-
significant. We believe that binding is not catalytically competent.  
Overall, in our studies we cannot make definite claims about our SPR data due to an 
inaccurate fitting model. We can however establish that (1) formation of the TG2: α-synuclein 
complex is obtainable in the absence of Ca2+, (2) Ca2+ role in the activation of TG2 appears to 
differentially affect the association of the complex, and (3) ionic strength appears to affect the 
association of the complex. With increased Ca2+ levels being a characteristic of physiological 
damage in neuronal cells, it does appear that high concentrations of Ca2+ are affecting complex 
formation.
 
Section. 3 IDENTIFYING Ca2+ BINDING SITES AND CONFORMATIONAL CHANGES 
TO THE ENZYME: SUBSTRATE COMPLEX 
Introduction 
TG2 is capable of binding six Ca2+ ions. It is theorized that all six sites need to be occupied in 
order for catalytic turnover to take place [21]. The location of these Ca2+ binding sites however 
are in question. There are no known crystal structures of TG2 that have Ca2+ bound to the 
enzyme [21,27]. In addition, there is also uncertainty concerning if Ca2+ binding follows a 
cooperative mechanism. Ca2+ binding in certain regions of TG2 can potentially be more 
favorable depending on the conformational state of the enzyme. It is proposed that TG2 has a 
Ca2+ binding region that is buried near the catalytic core. Availability to this site is limited unless 
there is a conformational change that reveals the site [21,27]. This Ca2+ binding site is also 
hypothesized to be more critical for TG2 catalytic activity.  Recent literature has predicted Ca2+ 
binding regions by performing multiple sequence alignments with transglutaminase 3 (TG3) and 
Factor XIII. These proteins are homologous to TG2 and contain Ca2+ binding regions that are 
evolutionary conserved. TG3 has three Ca2+ binding sites in its structure while Factor XIII 
contains one (Figure 18) [1,13]. Using the predicted Ca2+ binding regions, the literature created 
Ca2+ binding knock-outs of TG2. Along with the alignments, the study also looked the primary 
sequence of TG2 and proposed two more Ca2+ binding spots based off negatively charged 
regions [21]. The study synthesized Ca2+ knockout mutations of these sites as well (Figure 19; 
Table 7). The overall goal from the literature was to identify Ca2+ binding sites on TG2, in which 
they accomplished.
 








Figure 18:  Sequence alignments between TG2 homologs. Global sequence alignments between TG2: 
TG3 and TG2: Factor XIII. Alignments were performed using Clustal. Ca2+ binding sites are marked 
in yellow. 
 




Figure 19:  Proposed Ca2+ binding sites. Proposed Ca2+ binding sites in the “open” and “closed” conformations [17,27]. PDB 2Q3Z; 
4PYG 
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Table 7: Mutagenized regions of TG2 
Mutant Original Sequence Mutant Sequence 
S1 228 V N C N D D Q G V 228 V S C S N N Q G V 
S2A 395 A E V N A D V 395 A Q V S A N V 
S2B 445 Y P E G S S E E R E A  445 Y P Q G S S Q Q R Q A 
S3A 305 H D Q N S N L 305 H N Q S S S L 
S3B 326 D K S E M I W N 326 D K S Q M I W N 
S4 149 Y L D S E E E R Q E Y 149 Y L N S Q Q Q R Q Q Y 
S5 432 G R D E R E D I T 432 G R N Q R Q N I T 
 
An attempt to create our own mutations using bioinformatics was carried out. We aligned 
TG2 with calcium binding proteins that contain canonical binding regions (Table 8) [23]. 
Although the Ca2+ binding regions on TG2 are known to be noncanonical, it is possible that the 
regions could be semi-comparable to known Ca2+ binding regions on known proteins. Primarily, 





Table 8: List of calcium binding proteins used for alignments 
Calcium Binding 
Protein 





Calmodulin 4 P0DP23  
Parvalbumin 2 P20472  
Calcineurin 4 P63098  
Calbindin 4 P05937  
Recoverin 2 P35243  
Neurocalcin 3 P61601  
Calretinin 6 Q08331  
 
There are also questions regarding TG2 structure after complex formation with Ca2+. 
Preliminary data shows that TG2 undergoes a large conformational change during Ca2+ and 
substrate binding [20, 34]. However, the structure of the enzyme after complex formation has not 
been identified. We seek to find what happens structurally to TG2 after the full complex has 
formed, and also any further conformations when Ca2+ binds. We first wanted to observe 
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lanthanide interactions with TG2 and establish binding. Lanthanides are known to have the 
ability to bind to Ca2+ binding regions but with a higher affinity than Ca2+ [3-4,5,37]. They also 
have the ability to luminesce when excited, which can be measured by using a fluorometer. We 
have chosen Terbium as our model lanthanide for experimentation due to its easily observable 
emission wavelength at 546 nm.  
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Methods and Materials 
Materials 
All chemicals were purchased from VWR International (Radnor, PA). 
 
Overexpression and Purification of protein 
Refer to Section 2 
 
Bioinformatics 
Local sequence alignments were performed through the EMBOSS Water program [European 
Bioinformatics Institute]. Sequences of Transglutaminase 2 and other calcium binding proteins 
were blasted using UniProt and pasted into the Water program (BLOSUM62). The program 
provided the best fit and gave a description on the identity, similarity, and any gaps present in the 
alignment. 
 
Terbium Binding Experiments 
All binding experiments were performed on a spectrofluorometer. Experimental conditions 
consisted of 20 mM MOPS pH 7.2, 150 mM NaCl, 10 mM EGTA, and 1 mM DTT. Terbium 
stock concentration was 30 mM. TG2 concentration was kept at a constant 1.8 PM. C277A and 
α-synuclein concentrations were kept constant at 1 PM. Terbium was titrated at a constant 
volume of 1 PL. Terbium was excited at 259 nm and emission was measured from 250 to 700 
nm. A reading was taken after each titration. Background emission was removed. 
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Results 
Multiple sequence alignments between TG2 and known Ca2+ binding proteins 
We investigated similarities between TG2 and Ca2+ binding proteins to identify possible sites for 
Ca2+ binding. The Ca2+ binding proteins used are known to contain canonical binding regions. 
Sequences were aligned in the water program and tested for similarities. Local sequence 
alignments are displayed in Table 9. Results of alignments are presented in Figure 20. 
 
Measuring terbium binding by increase in luminescence 
We investigated if additional conformational changes occur to the complex once Ca2+ is added. 
We used terbium to measure changes in luminescence. Resulting graphs from terbium emission 
at 524, 565, and 595 nm into TG2, α-synuclein, C277A, and the C277A: α-synuclein complex 
are shown below (Figure 21). Plots comparing maximum fluorescence to terbium concentration 
are also shown below (Figure 22). Plots were corrected for background signal. 
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Table 9: Local sequence alignments with TG2 and Ca2+ binding proteins 




Best Alignment (EMBOSS Water) Identity Similarity Gaps Score 
Calmodulin 4 60 EGRGYEASVD     69  
   :|.||.::.:  
3  DGNGYISAAE     12  
3/10 
(30%) 
7/10 (70%) 0/10 (0%) 22.0 
Parvalbumin 2 177 QQGFI    181  
    :.|||  
  4 KSGFI     8  
3/5 
(60%) 
4/5 (80%) 0/5 (0%) 17.0 
Calcineurin 4 592 ERDLYLENPE    601  
    ::|.|:.|.|  
3   DKDGYISNGE     12  
4/10 
(40%) 
7/10 (70%) 0/10 (0%) 24.0 
Calbindin 4 583 YLENPE   588  
    |||..|  
7   YLEGKE    12 
4/6 
(66.7%) 
4/6 (66.7%) 0/6 (0%) 20.0 
Recoverin 2 187 DGILD    191  
    ||.||  
5   DGTLD      9  
4/5 
(80%) 
4/5 (80%) 0/5 (0%) 21.0 
Neurocalcin 3 116 RLSLE    120  
    :||||  
7   KLSLE     11  
4/5 
(80%) 
5/5 (100%) 0/5 (0%) 19.0 
Calretinin 6 114 LYRLSLE    120  
    |||..||  
6   LYRKDLE     12  
5/7 
(71.4%) 
5/7 (71.4%) 0/7 (0%) 23.0 
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Figure 20: Proposed Ca2+ binding sites from Ca2+ binding proteins. Depiction of 
Ca2+ binding sites derived from the local sequence alignments with known Ca2+ binding 
protein. Ca2+ binding regions are proposed to be residues 60-69, 114-120, 177-190, and 
583-601. Regions of interest are highlighted in magenta. Previously proposed Ca2+ 
binding sites are in yellow. PDB 2Q3Z 
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Figure 21:  Terbium binding with TG2. Measured terbium emission at wavelength 
524. Protein was excited at wavelengths 259, 280, and 295 nm. Arrows represent 
increased lanthanide binding to protein. Experimental conditions consisted of 20 mM 
MOPS pH 7.2, 150 mM NaCl, 10 mM EGTA, and 1 mM DTT. Terbium stock 
concentration was 30 mM. Starting TG2 concentration was 1.8 PM. Starting α-synuclein 
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C277A: α-syn (524 nm)
α-syn (524 nm)
Figure 22:  Luminescence increases due to terbium binding. Measured maximum luminescence from terbium binding with WT 
TG2, α-synuclein, and C277A: α-synuclein complex. Graphs focus on emission intensities at wavelength 524 nm. 
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Discussion 
We attempted to identify Ca2+ binding sites on TG2 by comparing the protein sequence with 
other Ca2+ binding proteins that contained canonical regions. With the alignments of their 
respective Ca2+ binding regions, we were able to establish four regions of interest on TG2: amino 
acid residues 60-69, 114-120, 177-190, and 583-601. The regions contain a noteworthy amount 
of negatively charged residues, which would make sense for Ca2+ to have an affinity towards it. 
The region at 114-120 however only contained one negative residue (Glu 120). It is likely that 
this region has a weak interaction with Ca2+. Regions also appear to be available on the surface 
of TG2’s structure. It is noteworthy that none of the regions discovered overlapped with 
proposed Ca2- binding sites from with previous literature. The regions are much more dispersed, 
as possible sites extend towards both of the termini. Although TG2 Ca2+ binding regions are 
considered non-canonical, it appears that TG2 shares similarities between canonical Ca2+ 
regions. It would be interesting to mutate the sites in these findings to determine if they have any 
adverse effect on complex formation or catalytic activity. 
Terbium showed ample fluorescence in assumed binding between WT TG2 and the 
C277A: α-synuclein complex. Terbium mixed with α-synuclein did not result in a strong 
response. This could be due to the lack of aromatic residues in the structure of α-synuclein, 
which is required for luminescence emission. It is also possible that α-synuclein cannot bind 
terbium, as there is little evidence of α-synuclein containing Ca2+ binding regions. TG2 binding 
with terbium showed a noteworthy increase of luminescence at around 50 PM terbium 
concentration. The C277A: α-synuclein complex did not share this same characteristic, as it 
appears to stay linear throughout additional titrations. We further plan to perform Luminescence 
Resonance Energy Transfer (LRET) to observe the conformational change following Ca2+ 
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binding. LRET is similar to FRET, with the exception of emission being due to luminescence 
[8,18]. We also plan on synthesizing TG2 mutants with tryptophan residues near potential Ca2+ 
binding regions to optimize luminescence [14,18]. We don’t know for sure if the increase is due 
to LRET or just a response to terbium binding. It would be insightful to use mutants that add 
tryptophan residues near proposed Ca2+ binding regions to determine if conformational changes 
are causing the inflation in the response. 
 
In summary, (1) alignments of TG2 with canonical Ca2+ binding proteins produced four 
unique binding regions, and (2) terbium’s interaction with TG2 and the TG2: α-synuclein 
showed noteworthy fluorescence. Identification of Ca2+ sites could be pivotal in our 
understanding in TG2’s uncontrolled mechanism in Parkinson’s disease.
 
Section 4. CONCLUSIONS AND FUTURE DIRECTIONS 
 
In this study we investigated Ca2+ role in the mechanism of TG2 activation. We aimed to obtain 
a better understanding of its mechanism in order to understand how this enzyme works in 
neurodegenerative diseases. We first demonstrated that Ca2+ isn’t necessary for TG2: α-synuclein 
complex formation. We went on to observe that varying Ca2+ and ionic strength appear to have 
an effect on the association of the complex. We will have to fit our data to a more accurate model 
before we can provide claims about the nature of the interactions. Our next step would be to 
investigate how Ca2+ is affecting the catalytic activity of the enzyme. It is hypothesized that Ca2+ 
could have a role in dictating transamidation activity of TG2. We would expect to see significant 
changes in transamidation rates if Ca2+ concentrations were altered. We also located possible 
Ca2+ binding sites on TG2 using bioinformatics. Mutations of these sites that knockout the ability 
for Ca2+ to bind can confirm lack of significance in the for specific sites in the binding 
mechanism. These mutations will also be beneficial in future kinetic experiments. Mutations can 
identify significant sites for kinetic activity as well as establish cooperation between binding 
sites [19]. Finally, we demonstrated the ability of terbium to interact with TG2 and the TG2: α-
synuclein complex. We plan to synthesize mutations that add tryptophan residues near proposed 
Ca2+ binding regions to maximize LRET. This will give insight on further conformational 
changes to the enzyme: substrate complex after Ca2+ binding. We continue to learn about this 
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